Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Gilead Sciences CEO Daniel O'Day has reported a planned sale of 10,000 shares of common stock for $113.63 per share, scheduled for August 28, 2025, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, executed pre-planned transactions, exercising stock options and selling common stock on August 15, 2025, under a Rule 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of common stock for $118.53 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chairman and CEO, Daniel Patrick O'Day, sold 10,000 shares of common stock on July 28, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' EVP, Corporate Affairs & GC, Deborah H. Telman, reported the acquisition of common stock through restricted stock unit vesting and a related disposal for tax purposes.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, has filed a Form 4 disclosing a planned sale of 3,000 shares of common stock on July 15, 2025, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 2,500 shares of common stock for $111.03 per share under a Rule 10b5-1 trading plan.

Gilead Sciences Director Jeffrey Bluestone exercised non-qualified stock options and subsequently sold an equal number of common shares on July 14, 2025, under a Rule 10b5-1 trading plan.

Gilead Sciences' Chairman and CEO, Daniel Patrick O'Day, sold 10,000 shares of common stock for approximately $1.1 million through a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, has filed a Form 4 disclosing a future sale of 2,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, sold 3,000 shares of common stock for $110.17 per share on June 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Diane E. Wilfong, Interim Corporate Controller and CAO of Gilead Sciences, Inc., reported the acquisition of common stock through the vesting of restricted stock units and a subsequent sale to cover tax obligations.

Gilead Sciences' EVP, Corporate Affairs & General Counsel, Deborah H. Telman, reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Gilead Sciences, Inc.'s Chief Commercial Officer, Johanna Mercier, reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Gilead Sciences, Inc. CEO and Chairman Daniel P. O'Day reported the acquisition of common stock through restricted stock unit conversion and a subsequent disposition for tax withholding purposes.

Gilead Sciences, Inc.'s Chief Financial Officer, Andrew D. Dickinson, reported the acquisition of common stock through the vesting of restricted stock units and the subsequent disposition of shares for tax withholding purposes.

Gilead Sciences, Inc., a 10% owner and director of Xilio Therapeutics, Inc., has acquired over 13 million units of prefunded and multi-series warrants, signaling a substantial investment in the biotechnology firm.

Gilead Sciences Chairman and CEO Daniel Patrick O'Day sold a total of 10,000 shares of common stock on May 30, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, executed a series of transactions on May 22, 2025, involving the exercise of stock options and subsequent sale of common stock, all conducted under a pre-established Rule 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, sold 2,500 shares of common stock at a price of $99.82 per share on May 15, 2025, according to a Form 4 filing with the SEC.

Director Sandra Horning reports the acquisition of stock options and restricted stock units (RSUs) in Gilead Sciences, Inc.

Director Harish Manwani reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Director Kelly A. Kramer reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Director Jeffrey Bluestone reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Director Anthony Welters reports acquisition of restricted stock units and stock options in Gilead Sciences, Inc.

Director Javier Rodriguez reports acquisition of restricted stock units and stock options in Gilead Sciences.

Director Ted W. Love reports acquisition of Gilead Sciences stock and stock options, including 1,516 restricted stock units and options to purchase 6,809 shares, all vesting immediately.

Director Jacqueline K. Barton reports acquisition of restricted stock units and stock options in Gilead Sciences, Inc.

Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, reports transactions involving common stock and restricted stock units.